Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Debt to Equity: 2023-2025

Historic Debt to Equity for Inhibrx Biosciences (INBX) over the last 1 years, with Sep 2025 value amounting to $2.71.

  • Inhibrx Biosciences' Debt to Equity was N/A to $2.71 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.71, marking a year-over-year change of. This contributed to the annual value of $4.76 for FY2023, which is N/A change from last year.
  • Inhibrx Biosciences' Debt to Equity amounted to $2.71 in Q3 2025, which was up 87.35% from $1.45 recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Debt to Equity peaked at $4.76 during Q4 2023, and registered a low of $1.04 during Q1 2025.
  • For the 2-year period, Inhibrx Biosciences' Debt to Equity averaged around $2.49, with its median value being $2.08 (2025).